✦ LIBER ✦

Rheumatoid arthritis: Methotrexate-first strategy valid in early poor-prognosis RA

Book ID: 120420126
Publisher: Nature Publishing Group
Year: 2013
Tongue: English
Weight: 50 KB
Volume: 9
Category: Article
ISSN: 1759-4790
DOI: 10.1038/nrrheum.2013.84

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Should We Use Poor Prognosis Factors to

Should We Use Poor Prognosis Factors to Start Early Treatment in Patients With Rheumatoid Arthritis?

✍ Lara Valor; Inmaculada de la Torre Ortega 📂 Article 📅 2012 🏛 Elsevier Science 🌐 Spanish ⚖ 159 KB

Treatment of poor-prognosis early rheuma

Treatment of poor-prognosis early rheumatoid arthritis: A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone

✍ S. M. Proudman; P. G. Conaghan; C. Richardson; B. Griffiths; M. J. Green; D. McG 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

PAR19 CRITERIA-BASED INTERPRETATION OF S

PAR19 CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE IN EARLY RHEUMATOID ARTHRITIS (RA)

✍ M Cifaldi; R Sterz; B Dietz; J Chmiel; GT Spencer-Green 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Evaluation of two strategies (initial me

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial

✍ Soubrier, M.; Puechal, X.; Sibilia, J.; Mariette, X.; Meyer, O.; Combe, B.; Flip 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 189 KB

PMS58 COST-UTILITY ANALYSIS OF DIFFERENT

PMS58 COST-UTILITY ANALYSIS OF DIFFERENT TREATMENT STRATEGIES AFTER THE FAILURE OF FIRST BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS (RA) IN THE FINNISH SETTING

✍ Hallinen, TA; Soini, EJ; Eklund, K; Puolakka, K 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Very early treatment with infliximab in

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial

✍ Mark A. Quinn; Philip G. Conaghan; Philip J. O'Connor; Zunaid Karim; Adam Greens 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views